Literature DB >> 16449804

Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.

Hideaki Yamasawa1, Yukihiko Sugiyama, Masashi Bando, Shoji Ohno.   

Abstract

A 74-year-old man with idiopathic pulmonary fibrosis (IPF) developed severe dyspnea on exertion after the readministration of imatinib mesylate for chronic myeloid leukemia. Chest X-ray and CT showed ground-glass opacities in both lungs in addition to preexisting honeycombing. Discontinuation of imatinib and methylprednisolone pulse therapy followed by administration of oral prednisolone resulted in improvement in both symptoms and radiographic findings. Imatinib-induced pneumonitis was diagnosed based on the clinical course and findings. Only five previous reports of imatinib-induced pneumonitis have been published in the literature, and this is the first case reported in a patient with IPF. 2006 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449804     DOI: 10.1159/000091272

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

Review 1.  Pulmonary toxicities from targeted therapies: a review.

Authors:  Nicholas A Barber; Apar Kishor Ganti
Journal:  Target Oncol       Date:  2011-11-11       Impact factor: 4.493

Review 2.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

3.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

4.  Impairments that influence physical function among survivors of childhood cancer.

Authors:  Carmen L Wilson; Prasad L Gawade; Kirsten K Ness
Journal:  Children (Basel)       Date:  2015

5.  A case of imatinib-related obstructive bronchiolitis followed long term.

Authors:  Chika Yajima; Nariaki Kokuho; Kazutoshi Toriyama; Junichiro Kawagoe; Yuki Togashi; Jun Matsubayashi; Hideaki Nakayama; Yasuhiro Setoguchi; Shinji Abe
Journal:  Respir Med Case Rep       Date:  2020-04-04

6.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.